Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Rosiglitazone For Type 2 Diabetes Does Not Increase Risk Of Cardiovascular Disease Or Death But Increases Heart Failure And Fractures In Women
Using rosiglitazone (Avandia) in combination with standard diabetes treatments (metformin or a sulfonylurea) to lower blood glucose in type 2 diabetics does not increase the risk of cardiovascular disease or death. However, the study confirms that using rosiglitazone more than doubles the risks of heart failure, and also increases the risk of fractures, mainly in women. The findings of the RECORD study are published in an Article Online First and in an upcoming edition of The Lancet. They are being simultaneously presented at the American Diabetes Association (ADA) meeting in New Orleans, USA.

The Publics' Ignorance Of Anatomy Revealed By Study
A study of patients and members of the public has shown that most lack even basic knowledge of human anatomy. The research, featured in the open access journal BMC Family Practice, found that people were generally incapable of identifying the location of major organs, even if they were currently receiving relevant treatment.
News of the day
Provectus Reports Encouraging Clinical Data At ASCO On Treatment Of Metastatic Melanoma With PV-10
Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has announced interim data from the first 40 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma. PV-10 treatment was well tolerated and caused selective tumor destruction in the majority of subjects. Additional data on untreated tumors corroborated observations of a possible bystander effect seen during earlier Phase 1 testing. These data were presented today at the American Society of Clinical Oncology 2009 Annual Meeting, Abstract #9060, entitled "Chemoablation of melanoma with intralesional rose bengal (PV-10)," in the General Poster Session.
Nutrition

Transatlantic Co-Operation Leads To Major Scientific CMOS (sCMOS) Technology Breakthrough

CMOS image sensor (CIS) technology stands on the brink of fulfilling its potential to become the global detector platform of choice for scientific photonics applications that require world class performance in the fields of sensitivity, speed, dynamic range, resolution, and field of view. The results of pioneering work, pooled res and shared expertise by scientists from Andor Technology (Northern Ireland), Fairchild Imaging (United States) and PCO (Germany) were revealed yesterday with the publication of a ground-breaking white paper at the Laser Conference and Exhibition in Munich (15 - 18 June 2009). The document presents sCMOS, a breakthrough technology based on next-generation CIS design and fabrication techniques. sCMOS is poised for widespread recognition as a true scientific grade CIS, capable of out-performing most scientific imaging devices on the market today. Unlike previous generations of CMOS and CCD-based sensors, sCMOS is uniquely capable of simultaneously offering: extremely low noise, rapid frame rates, wide dynamic range, high quantum efficiency (QE), high resolution, and a large field of view. "This announcement is a great moment for all three companies, who have come together in a true spirit of commitment to reach a shared goal," said Fairchild Imaging"s Colin Earle. "We have reached a "leap forward" point, where we can confidently claim that the next significant wave of advancement in high-performance scientific imaging capability has come from the CIS technology stable" added Dr. Colin Coates, Andor Technology. Dr. Gerhard Holst, PCO, said "Scientific CMOS (sCMOS) technology stands to gain widespread recognition across a broad gamut of demanding imaging applications, carrying an advanced set of performance features that renders it entirely suitable to high fidelity, quantitative scientific measurement." Current scientific imaging technology standards suffer limitations in relation to a strong element of "mutual exclusivity" between performance parameters, i.e. one can be optimized at the expense of others. sCMOS can be considered unique in its ability to concurrently deliver on many key parameters, whilst eradicating the performance drawbacks that have traditionally been associated with conventional CMOS imagers. Performance highlights of the first sCMOS technology sensor include: - Sensor format: 5.5 megapixels (2560(h) x 2160(v)) - Read noise: 16,000:1 (@ 30 frames/s) - QEmax.: 60% - Read out modes: Rolling and Global shutter (user selectable) Key applications for this new technology, already identified by Andor Technology, Fairchild Imaging and PCO include: - Live cell microscopy - Particle Imaging Velocimetry (PIV) - Single Molecule Detection - Super resolution microscopy - Lucky astronomy/imaging - Adaptive optics - Solar astronomy - Luminescence - Fluorescence Spectroscopy - Bio- and Chemo-Luminescence - Genome sequencing (2nd and 3rd generation) - High content screening - Biochip reading - Photovoltaic inspection - X-ray tomography - Machine vision - TV/Broadcasting - Spectral (hyperspectral) imaging - TIRF - Spinning disk confocal microscopy - FRET - FRAP - Laser Induced Breakdown spectroscopy Andor Technology


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009